CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine
- 664 Downloads
Purpose of Review
CGRP is a key neuropeptide in migraine pathophysiology. The blockade of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the interruption of trigeminal nerve system-mediated headache syndromes such as migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway have been developed and are currently under investigation for episodic (EM) and chronic migraine (CM) prevention. Here, we report data from these clinical trials.
Placebo-controlled, randomized double-blind phase studies of CGRP mAbs in episodic and chronic migraine have shown that the specific blockade of the peptide or the CGRP receptor are both powerful mechanisms to reduce migraine frequency. Along with the reduction of acute migraine-specific medication intake, early onset of efficacy of mAbs has been demonstrated. Most common adverse events are injection sider reactions. Depending on the mAb, the administration mode is a monthly or even less frequently s.c. or I.V. formulation.
Phase II studies in EM and CM demonstrate that CGRP mAbs are effective anti-migraine preventatives with a beneficial adverse event profile. Further detailed results from larger phase III clinical trials are expected soon.
KeywordsChronic migraine Episodic migraine CGRP antibody Migraine prevention Antibody safety
Compliance with Ethical Standards
Conflict of Interest
UR is a consultant or scientific advisor for Allergan, Amgen, Autonomic Technologies, Eli Lilly, Electrocore, Novartis, and Teva and has received honorarium from these companies for scientific presentations. H Israel and L Neeb have received honoraria from Pharm Allergan, Eli Lilly (LN), Electrocore Novartis (LN), and Autonomic Technologies. UR, LN, and HI are involved as investigators in clinical trials with mAbs from Amgen, Eli Lilly, Novartis, and Teva without personal remuneration.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 8.Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56:1280–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden Of Migraine Study (IBMS-II). Headache. 2013;53:644–55.CrossRefPubMedGoogle Scholar
- 10.•• Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091–100. The first phase II trial of a mAbs CGRP receptor antagonist for chronic migraine prevention. CrossRefPubMedGoogle Scholar
- 14.•• Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–34. The first phase II trial of a mAbs CGRP receptor antagonist for chronic migraine prevention. CrossRefPubMedGoogle Scholar
- 16.•• Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–92. The first phase II trial of a mAbs CGRP antagonist for migraine prevention. CrossRefPubMedGoogle Scholar
- 17.Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomized, double blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100–7.CrossRefPubMedGoogle Scholar
- 18.Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicenter, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081–90.CrossRefPubMedGoogle Scholar
- 19.•• Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382–9. The first phase II trial of a mAbs CGRP receptor antagonist for migraine prevention. CrossRefPubMedGoogle Scholar